The triglyceride-high-density lipoprotein axis: an important target of therapy?

Area of Science:

• Cardiology
• Lipidology
• Metabolic Syndrome Research

Background:

• Coronary heart disease (CHD) is a leading cause of death in the US.
• While low-density lipoprotein cholesterol (LDL-C) is a known CHD risk factor, triglycerides (TG) and high-density lipoprotein cholesterol (HDL-C) also play significant roles.
• Abnormalities in the TG-HDL axis, characterized by high TG and low HDL-C, are common in metabolic syndrome and associated with type 2 diabetes and CHD.

Purpose of the Study:

• To review the association of the TG-HDL axis with CHD.
• To discuss current and emerging therapeutic strategies for managing TG-HDL abnormalities.
• To highlight the need for further clinical trials on TG-HDL-targeted therapies.

Main Methods:

• Literature review of studies on lipid profiles and cardiovascular disease.
• Analysis of the role of TG and HDL-C in CHD pathogenesis.
• Evaluation of current and investigational pharmacologic treatments.

Main Results:

• High TG and low HDL-C are independently associated with increased CHD risk.
• The TG-HDL axis abnormality is a key feature of metabolic syndrome.
• Existing treatments include statins, fibrates, niacin, and fish oils, with new agents under investigation.

Conclusions:

• Aggressive lifestyle changes are recommended for patients with high TG and low HDL-C.
• Lipid-modifying therapy targeting the TG-HDL axis should be considered for high-risk individuals.
• More clinical trial data is required to confirm the efficacy of TG-HDL-targeted therapies in reducing cardiovascular events.